Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 10/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 10/20 | 0.49 |
| ▸ | PARP1 | P09874 | 4/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20931325 | 0.83 | MMP13 (0.45) | PARP1POLBKDM4EKMT2AALDH1A1 | |
| SCHEMBL20837068 | 0.81 | G6PD (0.51) | TNKS2PARP1POLBKDM4EMEN1 | |
| SCHEMBL164147 | 0.78 | TNKS (0.54) | TNKSTNKS2PARP1PARP2PARP14 | |
| SCHEMBL8188263 | 0.74 | TNKS (0.53) | TNKSTNKS2PARP1PARP2PARP14 | |
| SCHEMBL1387202 | 0.72 | TNKS2 (0.66) | TNKSTNKS2PARP1PARP2PARP14 | |
| SCHEMBL17298078 | 0.72 | TNKS2 (0.60) | TNKSTNKS2PARP1PARP2PARP14 | |
| SCHEMBL20836961 | 0.71 | F2RL3 (0.39) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL20837164 | 0.71 | TSHR (0.44) | POLBKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL21127496 | 0.70 | PARP14 (0.60) | TNKSTNKS2PARP1PARP2PARP14 | |
| SCHEMBL8105959 | 0.70 | POLB (0.47) | POLBKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | TNKS 531/4885TNKS2 932/4885PARP1 1342/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | TNKS 531/4885TNKS2 932/4885PARP1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.